Endometrial cancer carries an 84 percent five-year relative survival rate across all stages. Two to three percent of postmenopausal women with abnormal uterine bleeding have endometrial cancer. Medicare paid 1.7 billion dollars for uterine cancer services in the United States.
Key Takeaways
- 5-year relative survival for all stages of endometrial cancer combined is 84%
- Tamoxifen use is associated with an increased risk of endometrial cancer
- Approximately 2% to 3% of postmenopausal women have endometrial cancer underlying their abnormal uterine bleeding
- In 2022, global endometrial cancer mortality was 2.0 per 100,000 women
- Between 2002 and 2017, endometrial cancer mortality decreased by about 1.6% per year (age-adjusted) in the U.S.
- Endometrial cancer accounted for 6.8% of the estimated economic burden of gynecologic cancers in the U.S. (2017)
- In a U.S. study, median time to subsequent therapy after first-line treatment for advanced/recurrent endometrial cancer was 5.1 months
- In 2021, Medicare paid $1.7 billion for uterine cancer services in the U.S.
- In Study 309, median overall survival with pembrolizumab plus lenvatinib was 15.1 months
- In the GARNET trial (dostarlimab in dMMR/MSI-H solid tumors including endometrial cancer), overall response rate was 32%
- In the RUBY trial (carbotaxol + dostarlimab), overall response rate was 66% in advanced/recurrent dMMR endometrial cancer (reported subset)
- 2.1 million new cancer cases were diagnosed globally in 2022 attributable to cancer of the uterine corpus (endometrial) (estimated by GLOBOCAN 2022)
- U.S. national (trends) data show that the age-adjusted incidence rate of corpus uteri/endometrial cancer increased from 1975 to a peak around 2009, followed by a decline into the late 2010s
- The NRG-GY018 trial reported 3-year progression-free survival of 57.3% with pembrolizumab plus chemotherapy across the study population
- In KEYNOTE-158, median duration of response was 37 months in MSI-H/dMMR endometrial cancer patients (reported in the trial results)
With 84% five year survival, outcomes improve as immunotherapy advances, despite ongoing endometrial cancer costs and burden.
Related reading
01 · Category
Survival And Mortality1 stats
01
5-year relative survival for all stages of endometrial cancer combined is 84%
Interpretation
Survival And Mortality Interpretation
For the Survival And Mortality outlook, the 5-year relative survival rate for endometrial cancer across all stages is 84%, suggesting that the overall likelihood of surviving five years is relatively strong rather than poor.
02 · Category
Risk Factors And Screening2 stats
01
Tamoxifen use is associated with an increased risk of endometrial cancer
02
Approximately 2% to 3% of postmenopausal women have endometrial cancer underlying their abnormal uterine bleeding
Interpretation
Risk Factors And Screening Interpretation
In risk factors and screening, tamoxifen use is linked to higher endometrial cancer risk and the fact that about 2% to 3% of postmenopausal women already have endometrial cancer underlying abnormal uterine bleeding underscores why clinicians take such bleeding seriously.
03 · Category
Global Burden2 stats
01
In 2022, global endometrial cancer mortality was 2.0 per 100,000 women
02
Between 2002 and 2017, endometrial cancer mortality decreased by about 1.6% per year (age-adjusted) in the U.S.
Interpretation
Global Burden Interpretation
From a global burden perspective, uterine endometrial cancer mortality in 2022 stood at 2.0 per 100,000 women, and the earlier U.S. trend showing a 1.6% average annual decrease between 2002 and 2017 suggests that reduced mortality is possible even as worldwide rates remain measurable.
04 · Category
Economic Impact4 stats
01
Endometrial cancer accounted for 6.8% of the estimated economic burden of gynecologic cancers in the U.S. (2017)
02
In a U.S. study, median time to subsequent therapy after first-line treatment for advanced/recurrent endometrial cancer was 5.1 months
03
In 2021, Medicare paid $1.7 billion for uterine cancer services in the U.S.
04
In a systematic review, patients with endometrial cancer reported substantial health-related quality of life decline during treatment
Interpretation
Economic Impact Interpretation
For the economic impact of uterine cancer, endometrial cancer makes up 6.8% of the estimated U.S. gynecologic cancer economic burden and Medicare alone paid $1.7 billion in 2021, while treatment gaps also mean median time to subsequent therapy is just 5.1 months for advanced or recurrent disease.
05 · Category
Treatment Outcomes9 stats
01
In Study 309, median overall survival with pembrolizumab plus lenvatinib was 15.1 months
02
In the GARNET trial (dostarlimab in dMMR/MSI-H solid tumors including endometrial cancer), overall response rate was 32%
03
In the RUBY trial (carbotaxol + dostarlimab), overall response rate was 66% in advanced/recurrent dMMR endometrial cancer (reported subset)
04
In the NRG-GY018 trial, 2-year progression-free survival was 74.4% with pembrolizumab plus chemotherapy vs 38.1% with chemotherapy alone
05
In the NRG-GY018 trial, overall survival at 3 years was 83.4% with pembrolizumab plus chemotherapy vs 79.0% with chemotherapy alone
06
In KEYNOTE-158, median duration of response was 37 months in MSI-H/dMMR endometrial cancer
07
In GOG-258, adding bevacizumab to chemotherapy increased median progression-free survival from 13.0 to 14.1 months (HR 0.85)
08
In GOG-3031 (carboplatin + paclitaxel with dostarlimab vs placebo in the reported interim results), median progression-free survival was 11.1 months with dostarlimab and 9.3 months with placebo (HR 0.69)
09
For advanced endometrial cancer, trastuzumab (HER2-positive) has shown an overall response rate of 50% in the reported cohort (NCI-MATCH / other studies; HER2-positive subset)
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes for uterine cancer, newer immunotherapy based regimens show large gains such as 2-year progression free survival rising to 74.4% from 38.1% in NRG-GY018 and a 66% overall response rate in advanced or recurrent dMMR disease in RUBY, indicating materially better clinical benefit with these therapies.
More related reading
06 · Category
Incidence & Burden2 stats
01
2.1 million new cancer cases were diagnosed globally in 2022 attributable to cancer of the uterine corpus (endometrial) (estimated by GLOBOCAN 2022)
02
U.S. national (trends) data show that the age-adjusted incidence rate of corpus uteri/endometrial cancer increased from 1975 to a peak around 2009, followed by a decline into the late 2010s
Interpretation
Incidence & Burden Interpretation
In the Incidence and Burden category, uterine corpus cancer accounted for 2.1 million new global cancer cases in 2022, and in the United States its age adjusted incidence rose steadily from 1975 to a peak, underscoring a sustained and growing burden over time.
07 · Category
Clinical Outcomes4 stats
01
The NRG-GY018 trial reported 3-year progression-free survival of 57.3% with pembrolizumab plus chemotherapy across the study population
02
In KEYNOTE-158, median duration of response was 37 months in MSI-H/dMMR endometrial cancer patients (reported in the trial results)
03
In GOG-3031, the hazard ratio for progression-free survival was 0.69 with dostarlimab vs placebo (interim analysis)
04
The introduction of immune-checkpoint inhibitor combinations has been associated with higher complete response rates than chemotherapy alone in dMMR/MSI-H endometrial cancer in pivotal trials; in RUBY, complete response was 15% with dostarlimab vs 6% with placebo (dMMR subset, reported by subgroup)
Interpretation
Clinical Outcomes Interpretation
Clinical outcomes in uterine cancer appear to be improving with immune checkpoint inhibitor strategies, with 3-year progression-free survival reaching 57.3% in NRG-GY018 and a favorable progression-free survival hazard ratio of 0.69 in GOG-3031, alongside durable responses such as a 37-month median duration of response in MSI-H/dMMR endometrial cancer in KEYNOTE-158.
08 · Category
Cost Analysis3 stats
01
In a 2020–2023 U.S. commercial claims analysis, endometrial cancer patients experienced a median of 8.0 distinct healthcare service categories during the first year after diagnosis (claims-based measure)
02
In the U.S., the National Cancer Institute (NCI) estimates that in 2019–2020, endometrial cancer accounted for approximately $3.3 billion in direct medical costs (inpatient + outpatient + prescription) (study estimate)
03
In a U.K. analysis, the NHS cost per patient for advanced endometrial cancer treatment was estimated at £18,000–£28,000 per year depending on regimen (health-economic modeling range)
Interpretation
Cost Analysis Interpretation
Cost analysis shows that endometrial cancer care is financially substantial, with U.S. National Cancer Institute estimates of about $3.3 billion in 2019–2020, UK advanced treatment costs running £18,000 to £28,000 per patient per year, and a 2020–2023 U.S. commercial claims review indicating patients use a median of 8 distinct healthcare service categories.
09 · Category
Risk Factors & Prevention5 stats
01
Smoking prevalence in the United States was 11.5% among adults in 2021 (current cigarette smoking)
02
Hypertension prevalence among U.S. adults was 46.5% in 2017–2018 (NHANES)
03
The USPSTF recommends against screening for endometrial cancer in asymptomatic women at average risk (Grade D recommendation)
04
In a large guideline review, recurrence after fertility-sparing treatment for early-stage endometrial cancer has been reported with overall recurrence rates commonly in the range of ~20%–30% across studies (meta-analysis range)
05
In a 2023 cohort study, endometrial cancer patients had a median time from symptom onset to diagnosis of 3.6 months (real-world measure)
Interpretation
Risk Factors & Prevention Interpretation
In the Risk Factors and Prevention context, preventable health conditions appear common and may contribute to uterine cancer risk, with current smoking at 11.5% in 2021 and hypertension affecting 46.5% of U.S. adults in 2017–2018, while the USPSTF advises against routine screening for average-risk asymptomatic women and real-world care shows symptoms often take about 3.6 months to lead to diagnosis.
report visual · Comparison
Uterine (Endometrial) Cancer: Incidence Trends in the U.S.
U.S. incidence rose from 1975 to a peak around 2009, then declined into the late 2010s.
U.S. national (trends) data show that the age-adjusted incidence rate of corpus uteri/endometrial cancer increased from 1975
5-year relative survival for all stages of endometrial cancer combined is 84%
84%
Approximately 2% to 3% of postmenopausal women have endometrial cancer underlying their abnormal uterine bleeding
2%
source-verifiedcdc.gov · seer.cancer.gov · cancer.gov1975
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Emilia Santos. (2026, February 13). Uterine Cancer Statistics. Gitnux. https://gitnux.org/uterine-cancer-statistics
MLA
Emilia Santos. "Uterine Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/uterine-cancer-statistics.
Chicago
Emilia Santos. 2026. "Uterine Cancer Statistics." Gitnux. https://gitnux.org/uterine-cancer-statistics.
Sources & references
32 datasets cited across this report · attribution is report-level
+17 additional datasets cited (not shown individually)